Complete regress of a low-differentiated recurrence of the bladder cancer as the answer on two cycles of neoadjuvant polychemotherapy

Abstract

Complete regress of a low-differentiated recurrence of the bladder cancer as the answer on two cycles of neoadjuvant polychemotherapy

Author Biographies

P. G. Yakovlev, Bogomolets National Medical University, Kyiv

P. Yakovlev, Oncosurgeon, PhD, assistant professor,
Department of Urology
Bogomolets National Medical University.
13 Shevchenko Blvd., Kyiv, 01601 Ukraine.
(044) 234-40-62.
pavel_3@hotmail.com
https://orcid.org/ 0000-0002-1767-3231

S. V. Slyvka, Kyiv clinical railway hospital #3 at the branch "Center of health care" of PJSC "Ukrzaliznytsya", Kyiv

S. Slyvka, surgeon
Kyiv clinical railway hospital #3
8 Simferopolska St., Kyiv 02096, Ukraine.
044 566 3536.
n.slyvka@gmail.com
https://orcid.org/0000-0002-2061-0338

V. V. Chystyakov, Shupik National Medical Academy of Postgraduate Education, Kyiv

V. Chystiakou, clinical resident
department of urology,
Shupik National Medical Academy of Postgraduate Education,
Kyiv, 9 Dorogozhytska St, Kyiv 04112, Ukraine.
044 205 4946.
viktarchystsiakou@gmail.com
https://orcid.org/0000-0001-8771-824X

I. V. Globa, Kyiv clinical railway hospital #3 at the branch "Center of health care" of PJSC "Ukrzaliznytsya", Kyiv

I. Globa,Anesthesiologist.
Kyiv clinical railway hospital #3
8 Simferopolska St., Kyiv 02096, Ukraine
Phone: 044 566 3536.
E-mail: ivgloba@gmail.com
https://orcid.org/0000-0002-1027-1029

References

Witjes JA, Bruins M, Cathomas R, Compérat E, Cowan NC, Gakis G, et al. Muscle-invasive and Metastatic Bladder Cancer. EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona.: EAU Guidelines Office, Arnhem, Netherlands; 2019. Available from : https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/#7_8.

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018;16(9):1041-53. doi: 10.6004/jnccn.2018.0072.

Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol. 2012;61(5):1039-47. doi: 10.1016/j.eururo.2012.02.028.

Ghandour R, Singla N, Lotan Y. Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer. Trends Cancer. 2019;5(7):426-39. doi: 10.1016/j.trecan.2019.05.011.

Raphael MJ, Booth CM. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Underused across the 49. Can Urol Assoc J. 2019;13(2):29-31. doi: 10.5489/cuaj.5827.

Krabbe LM, Westerman ME, Margulis V, Raj GV, Sagalowsky AI, Courtney K, et al. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer. Can J Urol. 2015;22(4):7865-75. PMID: 26267024.

Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Malek R, Kübler H, et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018;36(2):43-53. doi: 10.1016/j.urolonc.2017.10.002.

Studer UE, Varol C, Danuser H. Orthotopic ileal neobladder. BJU Int. 2004;93(1):183-93. doi:10.1111/j.1464-410x.2004.04641.x.

Booth CM, Siemens DR, Li G, Peng Y, Tannock IF, Kong W, et al. Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer. 2014;120(11):1630-8. doi: 10.1002/cncr.28510.

McLaughlin S, Shephard J, Wallen E, Maygarden S, Carson CC, Pruthi RS. Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer. Int Braz J Urol. 2007;33(1):25-32. doi: 10.1590/s1677-55382007000100005.

Audenet F, Sfakianos JP, Waingankar N, Ruel NH, Galsky MD, Yuh BE, et al. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. Urol Oncol. 2019;37(2):116-22. doi: 10.1016/j.urolonc.2018.11.011.

Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859-66. doi: 10.1056/NEJMoa022148.

Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK, Trialists ICo, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171-7. doi: 10.1200/JCO.2010.32.3139

Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist. 2016;21(6):708-15. doi: 10.1634/theoncologist.2015-0440.

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(1):76-86. doi: 10.1016/S1470-2045(14)71160-X.

Booth CM, Tannock IF. Benefits of Adjuvant Chemotherapy for Bladder Cancer. JAMA Oncol. 2015;1(6):727-8. doi: 10.1001/jamaoncol.2015.1210.

Milowsky MI, Rumble RB, Booth CM, Gilligan T, Eapen LJ, Hauke RJ, et al. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016;34(16):1945-52. doi: 10.1200/JCO.2015.65.9797.

Goel S, Sinha RJ, Bhaskar V, Aeron R, Sharma A, Singh V. Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade. Asian J Urol. 2019;6(3):222-9. doi: 10.1016/j.ajur.2018.06.006.

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211-4. doi: 10.1016/S1470-2045(10)70275-8.

Published
2020-05-26
How to Cite
Yakovlev, P. G., Slyvka, S. V., Chystyakov, V. V., & Globa, I. V. (2020). Complete regress of a low-differentiated recurrence of the bladder cancer as the answer on two cycles of neoadjuvant polychemotherapy. Klinicheskaia Khirurgiia, 87(1-2), 100-103. https://doi.org/10.26779/2522-1396.2020.1-2.100
Section
Brief Communications